JP2023527794A5 - - Google Patents
Info
- Publication number
- JP2023527794A5 JP2023527794A5 JP2022572329A JP2022572329A JP2023527794A5 JP 2023527794 A5 JP2023527794 A5 JP 2023527794A5 JP 2022572329 A JP2022572329 A JP 2022572329A JP 2022572329 A JP2022572329 A JP 2022572329A JP 2023527794 A5 JP2023527794 A5 JP 2023527794A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- product according
- pharmaceutical product
- subject
- trastuzumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032223P | 2020-05-29 | 2020-05-29 | |
| US63/032,223 | 2020-05-29 | ||
| PCT/US2021/034715 WO2021243123A1 (en) | 2020-05-29 | 2021-05-28 | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527794A JP2023527794A (ja) | 2023-06-30 |
| JP2023527794A5 true JP2023527794A5 (https=) | 2024-05-29 |
Family
ID=76601765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572329A Pending JP2023527794A (ja) | 2020-05-29 | 2021-05-28 | トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230173067A1 (https=) |
| EP (1) | EP4157257A1 (https=) |
| JP (1) | JP2023527794A (https=) |
| KR (1) | KR20230027068A (https=) |
| CN (1) | CN115768416A (https=) |
| AU (1) | AU2021281336A1 (https=) |
| CA (1) | CA3183592A1 (https=) |
| IL (1) | IL298538A (https=) |
| MX (1) | MX2022014886A (https=) |
| WO (1) | WO2021243123A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120091828A (zh) * | 2022-10-12 | 2025-06-03 | 中外制药株式会社 | 含有肽、表面活性剂和聚合物的组合物 |
| WO2024130003A1 (en) * | 2022-12-15 | 2024-06-20 | Bolt Biotherapeutics, Inc. | Cancer combination treatment method |
| CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2012323890A1 (en) | 2011-10-14 | 2014-05-29 | Array Biopharma Inc. | Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them |
| WO2013056108A2 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| EP3344251B1 (en) * | 2015-09-04 | 2021-04-28 | Aslan Pharmaceuticals PTE Limited | A combination therapy comprising varlitinib and an anticancer agent |
| PT3589661T (pt) * | 2017-03-02 | 2024-01-29 | Genentech Inc | Tratamento com adjuvante de cancro da mama positivo para her2 |
| BR112019022280A2 (pt) * | 2017-04-28 | 2020-05-19 | Seattle Genetics Inc | tratamento de cânceres de her2 positivo |
| EP3727368A4 (en) * | 2017-12-19 | 2021-10-20 | Abraxis BioScience, LLC | METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY |
-
2021
- 2021-05-28 MX MX2022014886A patent/MX2022014886A/es unknown
- 2021-05-28 US US17/926,206 patent/US20230173067A1/en active Pending
- 2021-05-28 AU AU2021281336A patent/AU2021281336A1/en not_active Abandoned
- 2021-05-28 IL IL298538A patent/IL298538A/en unknown
- 2021-05-28 KR KR1020227044996A patent/KR20230027068A/ko active Pending
- 2021-05-28 EP EP21734645.1A patent/EP4157257A1/en active Pending
- 2021-05-28 JP JP2022572329A patent/JP2023527794A/ja active Pending
- 2021-05-28 WO PCT/US2021/034715 patent/WO2021243123A1/en not_active Ceased
- 2021-05-28 CN CN202180038814.2A patent/CN115768416A/zh active Pending
- 2021-05-28 CA CA3183592A patent/CA3183592A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2023502929A5 (https=) | ||
| JP2023534009A5 (https=) | ||
| CN108601831B (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| Higuchi et al. | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2) | |
| JP2023527794A5 (https=) | ||
| Abdel-Rahman | Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside | |
| JP2020517696A5 (https=) | ||
| JP2012509889A5 (https=) | ||
| US12213958B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| JP2012522837A5 (https=) | ||
| JP2023533937A5 (https=) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2023539589A5 (https=) | ||
| JP2022523045A5 (https=) | ||
| KR20240130081A (ko) | 항-trop-2 항체-약물 접합체와 추가 치료제의 병용 사용 | |
| JP2023537676A5 (https=) | ||
| Umemura et al. | Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience | |
| JP2022553041A5 (https=) | ||
| Wang et al. | Successes and failures of immunotherapy for gastric cancer | |
| Camera et al. | MOMENTUM: a phase I trial investigating 2 schedules of capecitabine with aflibercept in patients with gastrointestinal and breast cancer | |
| Fearon et al. | An energy and protein dense, high n-3 fatty acid oral supplement promotes weight gain in cancer cachexia | |
| JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| Hannan | 367eP Phase II trial of FTD/TPI and nal-IRI in advanced PDAC | |
| BR112020011796A2 (pt) | uso de tratamento combinado de anticorpo pd-1 e apati-nib para o tratamento de câncer de mama negativo triplo |